UZUN SÜRELİ PİPERASİLİN TAZOBAKTAM TEDAVİSİYLE GÖRÜLEN NÖTROPENİ: İKİ OLGU SUNUMU

Beta-laktam bir antibiyotik olan piperasilin ve piperasilin/tazobaktamın uzun süreli kullanımı, tüm diğer beta- laktamlar gibi kemik iliği süpresyonuna sebep olup nötropeni, trombositopeni veya pansitopeniye yol açabilmektedir. Bu etki kümülatif dozla ilgili olduğundan bu tedaviyi uzun süre alacak olan hastalarda dikkatli olunmalı ve hasta düzenli olarak tam kan sayımıyla kontrol edilmelidir. Bu çalışmada uzun süreli piperasilin/tazobaktam tedavisi almış ve nötropeni gelişmiş iki olgu sunulmuştur.

Development of Neutropenia During Treatment of Long Term Piperacillin/Tazobactam Therapy: Report of Two Cases

Long term use of piperacillin and piperacillin/tazobactam which are beta-lactam antibiotics, may cause bone marrow suppression and lead to neutropenia, thrombocytopenia or pancytopenia. This eff ect is related to the cumulative dose in pati- ents who receive this treatment, care must be taken f or a long term use and whole blood cell counts of patients should be monitored regularly.This paper presents two cases who had long term piperacillin/tazobactam therapy and developed neutropenia.

PDF

___

1. Bressler RB, Huston DP. Piperacillin-induced anemia and leukopenia, South Med J 1986;79(2):255-6. http://dx.doi.org/10.1097/00007611-198602000-00031 PMid:3945861
2. Julia A, Olona M, Bueno J et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes, Br J Haematol 1991;79(3):366-71. http://dx.doi.org/10.1111/j.1365-2141.1991.tb08042.x PMid:1751364
3. Kumar A, Choudhuri G, Aggarwal R. Piperacillin induced bone marrow suppression: a case report, BMC Clin Pharmacol 2003;3:2. http://dx.doi.org/10.1186/1472-6904-3-2 PMid:12791166 PMCid:PMC165417
4. Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics, J Inf ect Dis 1985;152(1):90-8. http://dx.doi.org/10.1093/infdis/152.1.90 PMid:4008995
5. Peralta FG, Sanchez MB, Roiz MP et al. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam, Clin Inf ect Dis 2003;37(11):1568-72. http://dx.doi.org/10.1086/379519 PMid:14614681
6. Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment-a retrospective analysis in 38 children with cystic fibrosis, Inf ection 1999;27(6):355-6. http://dx.doi.org/10.1007/s150100050042 PMid:10624596
7. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam, Br J Haematol 1996;95(4):611-2. http://dx.doi.org/10.1046/j.1365-2141.1996.d01- 1952.x PMid:8982034
8. Scheetz MH, McKoy JM, Parada JP et al. Systematic review of piperacillin-induced neutropenia, Drug Saf 2007;30(4):295-306. http://dx.doi.org/10.2165/00002018-200730040-00002 PMid:17408306
9. Singh N, Yu VL, Mieles LA, Wagener MM. Betalactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease, Am J Med 1993;94(3):251-6. http://dx.doi.org/10.1016/0002-9343(93)90056-U